ATRA - Atara Biotherapeutics director purchases 100K company shares
2023-11-15 13:09:37 ET
More on Atara Biotherapeutics
- Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity
- Atara's Balancing Act: Innovation On A Fiscal Tightrope
- Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript
- Atara stock plunges 50% after-hours on failed Phase 2 study for MS drug
- Mizuho values Atara's US tab-cel deal at $450M, or $4/share
For further details see:
Atara Biotherapeutics director purchases 100K company shares